High-dose 5-fluorouracil and leucovorin as second-line chemotherapy in patients with platinum-resistant epithelial ovarian cancer
- PMID: 7497592
- DOI: 10.1007/BF00685649
High-dose 5-fluorouracil and leucovorin as second-line chemotherapy in patients with platinum-resistant epithelial ovarian cancer
Abstract
A total of 14 patients with platinum-resistant advanced epithelial ovarian cancer were treated with a continuous infusion of high-dose 5-fluorouracil (5-FU, 1200 mg/m2 per day) for 2 consecutive days weekly for 4 weeks and, thereafter, every 2 weeks in combination with a push injection of folinic acid (20 mg/m2) given just before 5-FU and after 24 h. No objective response was documented, and only five patients showed stable disease. The median survival was 6.5 months. There was minimal toxicity. This schedule of 5-FU in combination with folinic acid is not effective as second-line chemotherapy in advanced ovarian cancer.
Similar articles
-
Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.Semin Oncol. 1996 Oct;23(5 Suppl 11):32-7. Semin Oncol. 1996. PMID: 8893897 Clinical Trial.
-
Oxaliplatin plus high-dose leucovorin and 5-fluorouracil (FOLFOX 4) in platinum-resistant and taxane-pretreated ovarian cancer: a phase II study.Gynecol Oncol. 2004 Oct;95(1):165-72. doi: 10.1016/j.ygyno.2004.06.029. Gynecol Oncol. 2004. PMID: 15385127 Clinical Trial.
-
Phase II evaluation of 5-fluorouracil and low-dose leucovorin in cisplatin-refractory advanced ovarian carcinoma.Gynecol Oncol. 1994 Aug;54(2):180-3. doi: 10.1006/gyno.1994.1190. Gynecol Oncol. 1994. PMID: 8063243 Clinical Trial.
-
Weekly high-dose infusional 5-fluorouracil (HD-5-FU) combinations in the treatment of advanced breast cancer: results of phase I/II studies with weekly 24-hour infusion of HD-5-FU plus high-dose folinic acid (FA) alone and in combination with paclitaxel and cisplatin.J Infus Chemother. 1996 Summer;6(3):127-32. J Infus Chemother. 1996. PMID: 9229323 Review.
-
Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies.Drugs. 2000 Oct;60(4):895-924. doi: 10.2165/00003495-200060040-00005. Drugs. 2000. PMID: 11085200 Review.
Cited by
-
Salvage therapy for ovarian cancer.Curr Oncol Rep. 1999 Sep;1(1):64-70. doi: 10.1007/s11912-999-0012-8. Curr Oncol Rep. 1999. PMID: 11122800 Review.
-
Checkpoint signaling, base excision repair, and PARP promote survival of colon cancer cells treated with 5-fluorodeoxyuridine but not 5-fluorouracil.PLoS One. 2011;6(12):e28862. doi: 10.1371/journal.pone.0028862. Epub 2011 Dec 15. PLoS One. 2011. PMID: 22194930 Free PMC article.
-
Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer.BMC Cancer. 2018 Dec 19;18(1):1267. doi: 10.1186/s12885-018-5180-1. BMC Cancer. 2018. PMID: 30567527 Free PMC article.
-
Epirubicin, Cisplatin, and Capecitabine for Primary Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer: Results of a Retrospective, Single-Institution Study.Int J Gynecol Cancer. 2015 Jul;25(6):977-84. doi: 10.1097/IGC.0000000000000448. Int J Gynecol Cancer. 2015. PMID: 25962114 Free PMC article. Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical